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index of GWBAS in EH was lower (80.0 ± 16.9 vs. 90.3
± 15.3 points; p < 0.0001) and the total complaints index
of GSCQ was higher (29.7 ± 17.4 vs. 15.9 ± 9.7 points;
p < 0.000001) compared with the healthy control.
CONCLUSIONS: Some discrepancies were revealed in
testing results of the studied QL measures in developed
and transitional societies. GWBAS and GSCQ demon-
strate sufﬁcient internal consistency reliability, convergent
and discriminate validity, as well as sensitivity and may be
used for the QL assessment in EH living in an unstable
economy. DHP seems to be less reliable, probably due to
brevity and intersected structure of subscales, and should
be applicable mainly for fast preliminary QL screening.
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OBJECTIVE: The Joint National Committee (JNC) 
on Detection, Evaluation, and Treatment of High Blood
Pressure V (1993) and VI (1997) recommended diuretics
and beta-blockers as initial antihypertensive drugs.
However, a few studies have shown a trend of the increas-
ing use of angiotensin-converting enzyme inhibitors
(ACEIs) and calcium channel blockers (CCBs), and the
decreasing use of diuretics and beta-blockers. Hyperten-
sion is one of the most common reasons for patients to
use clinic visits. The purpose of the study was to assess
the association between the different patterns of antihy-
pertensive drug use and the number of clinic visits for
essential hypertension.
METHOD: Poisson regression model was employed to
assess the association between the different patterns of
antihypertensive drug use and the number of clinic visits
by using the Medical Expenditure Panel Survey (MEPS,
1996), after controlling for confounding variables. The
study population enrolled was estimated 10,357,769
non-institutionalized adult US patients with essential
hypertension.
RESULTS: Patients with diuretics or beta-blockers had
fewer clinic visits, compared to patients with ACEIs or
CCBs (p < 0.01). Patients in good physical health had
fewer clinic visits, compared with patients in fair or poor
physical health (p < 0.05). Other signiﬁcant explanatory
variables include census region and limitations in daily
life activities. 
CONCLUSION: Patients using ACEIs or CCBs, which
were not recommended by the current JNC guidelines had
more clinic visits. This association needs to be concerned
in the management of hypertension.
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OBJECTIVE: To estimate the UK population of people
with type 2 diabetes who would be eligible for treatment
with ramipril for secondary prevention of cardiovascular
events, as deﬁned by the inclusion criteria of the MICRO
HOPE trial, as a basis for estimating the NHS budget
impact of treatment. 
METHOD: Patients were eligible to participate in the
MICRO HOPE trial if they were over 55 years of age
with diabetes and one other risk factor for cardio-
vascular disease (total cholesterol >5.2mmol/L, HDL 
cholesterol £0.9mmol/L, hypertension, known microal-
buminuria, or current smoking). Exclusion criteria
included dipstick positive proteinuria and present usage
of ACE inhibitors. We used published national prevalence
data to identify the number of people with Type 2 dia-
betes over 55 in the UK at present. In order to estimate
the percentage of these patients who would ﬁt the
MICRO HOPE inclusion criteria, we conducted a review
of the South Teeside Diabetes Register.
RESULTS: There were 6998 people with diabetes on the
South Teeside District Diabetes Register in 2000. 4,733
were over 55 years of age, and of these patients 2,777
had available data for proteinuria: 496 (18%) patient
tested positive, 2,281 (82%) were negative. 1,010 (36%)
patients had additional risk factors as well as being 
proteinuria negative and not being treated with an ACE
inhibitor. There are 816,000 people with Type 2 diabetes
who are over 55 years of age in the UK at present. We
estimate that 294,000 of these patients are eligible for
treatment with ramipril, as prescribed in the MICRO
HOPE trial, but are not presently being treated. For an
average Primary Care Trust with a population of 100,000
people, there are likely to be 493 patients eligible for
treatment. 
CONCLUSION: This estimate gives a measure of 
potential workload for NHS primary care prescribers,
and could populate a budget impact analysis study on 
the cost of implementing the MICRO HOPE trial 
recommendations.
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